Related Experiment Video
Updated: Jun 29, 2026
07:33
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
Preliminary communication: imiquimod in mixed capillary/lymphatic malformation
1Department of Dermatology, University of Palermo, Italy. istderm@unipa.it
Dermatologic Therapy
|December 17, 2008
Summary
Topical imiquimod effectively treated a pediatric patient's superficial capillary/lymphatic malformation. Lesions showed significant regression and no recurrence after treatment cessation.
Area of Science:
- Dermatology
- Vascular Malformations
Background:
- Mixed capillary/lymphatic malformations present a therapeutic challenge, especially in pediatric cases where destructive interventions may be undesirable.
- Understanding the mechanism of action of topical agents is crucial for developing effective treatment strategies.
Observation:
- A 14-year-old boy presented with a 7-year history of slowly growing, translucent, hemorrhagic vesicles and skin-colored nodules on his chin.
- Physical examination revealed multiple lesions consistent with a mixed capillary/lymphatic malformation.
Findings:
- Treatment with topical imiquimod resulted in decreased lesion protuberance after 4 weeks.
- Partial regression of the capillary component and normalization of skin color were observed after 2 months of therapy.
- Complete regression of the malformation was achieved one month after therapy termination, with no recurrence.
Implications:
- Topical imiquimod demonstrates efficacy in treating superficial mixed capillary/lymphatic malformations.
- This non-destructive therapeutic approach may be particularly beneficial for malformations where surgical or ablative methods are contraindicated.
- Further research into the precise mechanism of imiquimod in vascular malformations is warranted.
